Quince Therapeutics announced an all-stock reverse merger with privately held Orphai Therapeutics, according to a May 18 SEC filing. The merged company will keep Quince’s Nasdaq listing, with Quince stockholders owning only 6.9%, while Orphai shareholders and new investors will control the rest. The move comes after Quince’s failed phase 3 Neat trial in ataxia-telangiectasia and a search for strategic options, its cash runway extending only into the second quarter of 2026. Orphai contributes its lead asset, LAM-001, a rapamycin-based therapy in midstage development for pulmonary hypertension tied to interstitial lung disease. Orphai CEO Brigette Roberts, M.D., now joins Quince as chief of corporate affairs and board member.
The merger closes the book on Quince’s ambitions in rare disease and hands Orphai a ready-made public listing, an increasingly common tactic in biotech circles when small caps retool after major trial setbacks. Investors seem unlikely to see this as a value-generator; Quince shareholders’ tiny slice of the pie says as much. Yet the combination moves the new entity into a field with wider commercial reach than Quince’s prior focus on A-T. Pulmonary hypertension associated with interstitial lung disease remains a high-need area, with some regulatory momentum and growing investor attention around pulmonary assets. There’s at least a story to tell here.
Whether Orphai can turn this listing into sustainable capital and speed LAM-001 through development is another question. If it does, the merger will look shrewd in hindsight. If not, the market’s weariness toward biotech pivots will return fast. Either way, this transaction underlines a reality insiders already know, reverse mergers aren’t glamorous, just practical. Sometimes survival is the strategy, and Quince’s latest move fits that theme.
